Delstrigo is a fixed-dose combination tablet containing doravirine, lamivudine and tenofovir disoproxil. Delstrigo is manufactured by Merck.
Doravirine is a non-nucleoside reverse transcriptase inhibitor also marketed alone as Pifeltro. Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor and lamivudine is a nucleoside reverse transcriptase inhibitor.
These drugs reduce the amount of HIV in the body, prevent the development of AIDS-defining illnesses and prevent HIV being passed on during sex when the viral load is undetectable.
Delstrigo is approved in the European Union and the United States for the treatment of adults with previously untreated HIV infection. Delstrigo received approval in August 2018 in the United States and November 2018 in the European Union.
Delstrigo is dosed as one yellow tablet once a day, with or without food. Delstrigo contains 100mg of doravirine, 300mg of lamivudine and 245mg of tenofovir disoproxil.
Common side-effects of Delstrigo (occurring in more than one in a hundred people) include abnormal dreams, difficulty in sleeping, nightmare, depression, headache, dizziness, drowsiness, cough, an irritated or runny nose, nausea, diarrhoea, abdominal pain, vomiting, hair loss, rash, muscle disorders, fatigue, fever.
For more information on Delstrigo’s component drugs, including further details of potential side-effects, efficacy and drug resistance, see entries for doravirine, tenofovir and lamivudine.